Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911
Debt
Debt-to-Equity Ratio0.32
Current Ratio0.68
Quick Ratio0.68
Price-To-Earnings
Trailing P/E Ratio35.25
Forward P/E Ratio21.96
P/E Growth1.34
Sales & Book Value
Annual Sales$436.15 million
Price / Sales4.37
Cash Flow$2.6857 per share
Price / Cash19.95
Book Value$13.40 per share
Price / Book4.00
Profitability
EPS (Most Recent Fiscal Year)$1.52
Net Income$39.12 million
Net Margins10.44%
Return on Equity14.22%
Return on Assets7.79%
Miscellaneous
Employees2,500
Outstanding Shares35,570,000
Market Cap$1.87 billion
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Tuesday, July, 31st. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.19. The company earned $117.80 million during the quarter, compared to analysts' expectations of $104.97 million. Medpace had a net margin of 10.44% and a return on equity of 14.22%. The firm's quarterly revenue was up 24.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.38 EPS. View Medpace's Earnings History.
When is Medpace's next earnings date?
How can I listen to Medpace's earnings call?
Medpace will be holding an earnings conference call on Tuesday, October 30th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8002197113.
What guidance has Medpace issued on next quarter's earnings?
Medpace issued an update on its FY18 earnings guidance on Monday, July, 30th. The company provided earnings per share guidance of $2.51-2.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.93. The company issued revenue guidance of $461-473 million, compared to the consensus revenue estimate of $431.46 million.
What price target have analysts set for MEDP?
7 equities research analysts have issued 1-year price targets for Medpace's shares. Their predictions range from $35.00 to $63.00. On average, they anticipate Medpace's stock price to reach $42.8333 in the next twelve months. This suggests that the stock has a possible downside of 20.1%. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Medpace.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI) and Luna Innovations (LUNA).
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 62)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 44)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 55)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 49)
- Mr. Todd Meyers, VP of Bus. Devel. & Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?
Medpace's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (0.26%), Bowling Portfolio Management LLC (0.11%), Nisa Investment Advisors LLC (0.10%), Bank of Montreal Can (0.09%), Strs Ohio (0.05%) and Campbell Newman Asset Management Inc. (0.03%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Institutional Ownership Trends for Medpace.
Which institutional investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Insider Buying and Selling for Medpace.
Which institutional investors are buying Medpace stock?
MEDP stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Bowling Portfolio Management LLC, Nisa Investment Advisors LLC, Bank of Montreal Can, Campbell Newman Asset Management Inc. and Atria Investments LLC. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $53.58.
How big of a company is Medpace?
Medpace has a market capitalization of $1.87 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.
What is Medpace's official website?
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
